Mutated KRAS Is an Independent Negative Prognostic Factor for Survival in NSCLC Stage III Disease Treated with High-Dose Radiotherapy

Table 2

Prevalence, and relation to patient characteristics of EGFR mutations, KRAS mutations, and EGFR FISH positivity.

	EGFRmut	EGFR FISHpos	KRASmut
𝑛 =	5 = 7.5%	12 = 19.7%	19 = 28.8%
Inconclusive	2	8	3
Median age	62 (47–71)	62 (43–75)	62 (55–73)
Gender F/M	60/40%	67/33%	58/42%
PS 0/1	40/60%	50/50%	48/52%
Stage IIIA/IIIB	40/60%	17/83%	21/79%
Weight loss > 5%	20%	42%	32%
Histology
Adenocarcinoma	40%	42%	68.5%
SCC	40%	42%	10.5%
NSCLC NOS	20%	16%	21%